Patents by Inventor Juqun Shen

Juqun Shen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Bispecific antibodies targeting immune checkpoints
    Patent number: 11939381
    Abstract: The present invention relates to bispecific antibodies that antagonize human PD-1 and agonize human CD137, and may be useful for treating solid and hematological tumors alone and in combination with chemotherapy and ionizing radiation.
    Type: Grant
    Filed: July 12, 2019
    Date of Patent: March 26, 2024
    Assignee: Eli Lilly and Company
    Inventors: Stephen J. Demarest, Yiqing Feng, Juqun Shen, Yang Shen, Stephanie Marie Truhlar
  • BISPECIFIC ANTIBODIES TARGETING IMMUNE CHECKPOINTS
    Publication number: 20210292416
    Abstract: The present invention relates to bispecific antibodies that antagonize human PD-1 and agonize human CD137, and may be useful for treating solid and hematological tumors alone and in combination with chemotherapy and ionizing radiation.
    Type: Application
    Filed: July 12, 2019
    Publication date: September 23, 2021
    Inventors: Stephen J. DEMAREST, Yiqing FENG, Juqun SHEN, Yang SHEN, Stephanie Marie TRUHLAR
  • Anti-canine platelet derived growth factor receptor alpha antibody
    Patent number: 10711066
    Abstract: The present disclosure relates to anti-canine platelet derived growth factor receptor alpha antibodies binding to canine platelet derived growth factor receptor alpha.
    Type: Grant
    Filed: July 20, 2017
    Date of Patent: July 14, 2020
    Assignee: Elanco US Inc.
    Inventors: Douglas Bryan Burtrum, Dale Lincoln Ludwig, Juqun Shen, Cheng Wang
  • Anti-Canine Platelet Derived Growth Factor Receptor Alpha Antibody
    Publication number: 20190300612
    Abstract: The present disclosure relates to anti-canine platelet derived growth factor receptor alpha antibodies binding to canine platelet derived growth factor receptor alpha.
    Type: Application
    Filed: July 20, 2017
    Publication date: October 3, 2019
    Inventors: Douglas Bryan BURTRUM, DALE Lincoln LUDWIG, Juqun SHEN, Cheng WANG
  • PD-L1 Antibodies
    Publication number: 20190144544
    Abstract: The present invention relates to antibodies that bind human programmed cell death 1 ligand 1 (PD-L1), and may be useful for treating solid and hematological tumors alone and in combination with chemotherapy and other cancer therapeutics.
    Type: Application
    Filed: January 25, 2019
    Publication date: May 16, 2019
    Inventors: Dale Lincoln Ludwig, Marshall Davenport Snavely, Yiwen Li, Juqun Shen, Vera Molkenthin
  • PD-L1 antibodies
    Patent number: 10214586
    Abstract: The present invention relates to antibodies that bind human programmed cell death 1 ligand 1 (PD-L1), and may be useful for treating solid and hematological tumors alone and in combination with chemotherapy and other cancer therapeutics.
    Type: Grant
    Filed: August 18, 2016
    Date of Patent: February 26, 2019
    Assignee: Eli Lilly and Company
    Inventors: Dale Lincoln Ludwig, Marshall Davenport Snavely, Yiwen Li, Juqun Shen, Vera Molkenthin
  • PD-L1 Antibodies
    Publication number: 20170058033
    Abstract: The present invention relates to antibodies that bind human programmed cell death 1 ligand 1 (PD-L1), and may be useful for treating solid and hematological tumors alone and in combination with chemotherapy and other cancer therapeutics.
    Type: Application
    Filed: August 18, 2016
    Publication date: March 2, 2017
    Inventors: Dale Lincoln Ludwig, Marshall Davenport Snavely, Yiwen Li, Juqun Shen, Vera Molkenthin
  • Fibroblast growth factor receptor-1 inhibitors and methods of treatment thereof
    Patent number: 8263074
    Abstract: The present invention is directed to an antibody or fragments thereof that are specific for a fibroblast growth factor receptor (FGFR)-1(IIIb), FGFR-1(IIIc), and/or FGFR-4. Also, provided herein, are vectors and host cells comprising the nucleic acids encoding those antibodies. The present invention further provides methods of antagonizing FGFR-1 or FGFR-4 as a treatment for obesity, diabetes, or a condition related thereto, and methods of reducing food intake.
    Type: Grant
    Filed: December 16, 2011
    Date of Patent: September 11, 2012
    Assignee: ImClone LLC
    Inventors: Haijun Sun, Juqun Shen, James Robert Tonra
  • FIBROBLAST GROWTH FACTOR RECEPTOR-1 INHIBITORS AND METHODS OF TREATMENT THEREOF
    Publication number: 20120121609
    Abstract: The present invention is directed to an antibody or fragments thereof that are specific for a fibroblast growth factor receptor (EGFR)-1(IIIb), EGFR-1(IIIc), and/or EGFR-4. Also, provided herein, are vectors and host cells comprising the nucleic acids encoding those antibodies. The present invention further provides methods of antagonizing EGFR-1 or EGFR-4 as a treatment for obesity, diabetes, or a condition related thereto, and methods of reducing food intake.
    Type: Application
    Filed: December 16, 2011
    Publication date: May 17, 2012
    Applicant: IMCLONE LLC
    Inventors: Haijun SUN, Juqun SHEN, James R. TONRA
  • PDGFR BETA-SPECIFIC INHIBITORS
    Publication number: 20100221267
    Abstract: The invention is directed to novel PDGFR?-specific antagonists. The antagonists include antibodies, which can be bispecific. The antibodies are used to reduce or inhibit tumor growth and or to treat an angiogenic disease. The invention also includes combinations of PDGFR?-specific antagonists with VEGFR antagonists for such treatments. The antagonists can further be administered in combination with other anti-angiogenic or anti-neoplastic drugs.
    Type: Application
    Filed: April 21, 2010
    Publication date: September 2, 2010
    Applicant: IMCLONE LLC
    Inventors: Zhenping ZHU, Juqun SHEN
  • PDGFR?-specific antibodies
    Patent number: 7740850
    Abstract: The invention is directed to novel PDGFR?-specific antagonists. The antagonists include antibodies, which can be bispecific. The antibodies are used to reduce or inhibit tumor growth and or to treat an angiogenic disease. The invention also includes combinations of PDGFR?-specific antagonists with VEGFR antagonists for such treatments. The antagonists can further be administered in combination with other anti-angiogenic or anti-neoplastic drugs.
    Type: Grant
    Filed: April 17, 2008
    Date of Patent: June 22, 2010
    Assignee: ImClone, LLC
    Inventors: Zhenping Zhu, Juqun Shen
  • PDGFRbeta-specific inhibitors
    Publication number: 20090053241
    Abstract: The invention is directed to novel PDGFR?-specific antagonists. The antagonists include antibodies, which can be bispecific. The antibodies are used to reduce or inhibit tumor growth and or to treat an angiogenic disease. The invention also includes combinations of PDGFR?-specific antagonists with VEGFR antagonists for such treatments. The antagonists can further be administered in combination with other anti-angiogenic or anti-neoplastic drugs.
    Type: Application
    Filed: April 17, 2008
    Publication date: February 26, 2009
    Applicant: ImClone Systems Incorporated
    Inventors: Zhenping Zhu, Juqun Shen
  • Fibroblast Growth Factor Receptor-1 Inhibitors and Methods of Treatment Thereof
    Publication number: 20070274981
    Abstract: The present invention is directed to an antibody or fragments thereof that are specific for a fibroblast growth factor receptor (FGFR)-1(IIIb), FGFR-1(IIIc), and/or FGFR-4. Also, provided herein, are vectors and host cells comprising the nucleic acids encoding those antibodies. The present invention further provides methods of antagonizing FGFR-1 or FGFR-4 as a treatment for obesity, diabetes, or a condition related thereto, and methods of reducing food intake.
    Type: Application
    Filed: October 18, 2004
    Publication date: November 29, 2007
    Applicant: IMCLONE SYSTEMS INCORPORATION
    Inventors: Haijun Sun, Juqun Shen, James Tonra